Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 14/20 | 0.55 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | KAT7 | O95251 | 1/20 | 0.41 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.41 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21878465 | 0.88 | CHRM1 (0.57) | CHRM1 | |
| SCHEMBL21878448 | 0.83 | CHRM1 (0.74) | CHRM1 | |
| SCHEMBL21929402 | 0.81 | CHRM1 (0.58) | CHRM1CNR1CNR2 | |
| SCHEMBL21878490 | 0.80 | CHRM1 (0.64) | CHRM1 | |
| SCHEMBL21878478 | 0.80 | CHRM1 (0.71) | CHRM1 | |
| SCHEMBL21878458 | 0.79 | CHRM1 (0.51) | CHRM1 | |
| SCHEMBL21878500 | 0.79 | CHRM1 (0.72) | CHRM1 | |
| SCHEMBL21929477 | 0.79 | CHRM1 (0.47) | CHRM1 | |
| SCHEMBL21878499 | 0.78 | CHRM1 (0.49) | CHRM1 | |
| Lithium Ion SCHEMBL21878483 | 0.77 | CHRM1 (0.46) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131159-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | NIH-DEITR | 2020-04-30 | — | — | US | claimed |
| US-20200131159-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | NIH-DEITR | 2020-04-30 | — | — | US | disclosed |
| US-20200131159-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | NIH-DEITR | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131159-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885CNR1 46/4885CNR2 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.